CAS 1010100-07-8

CC-885

Description:

CC-885, with the CAS number 1010100-07-8, is a small molecule that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is primarily recognized as a selective inhibitor of the protein degradation pathway, specifically targeting the cereblon (CRBN) E3 ubiquitin ligase complex. This compound has shown promise in preclinical studies for its ability to modulate protein homeostasis and induce the degradation of specific oncoproteins, making it a candidate for cancer treatment. CC-885's mechanism of action involves disrupting the interaction between CRBN and its substrates, leading to the targeted degradation of proteins that contribute to tumorigenesis. Additionally, its chemical structure includes features that enhance its bioavailability and selectivity, which are critical for minimizing off-target effects. Ongoing research aims to further elucidate its pharmacokinetic properties, efficacy, and safety profile in various cancer models, paving the way for potential clinical applications.

Synonyms:

• Urea, N-(3-chloro-4-methylphenyl)-N'-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1-oxo-1H-isoindol-5-yl]methyl]-
• 1-(3-Chloro-4-methylphenyl)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)urea

CC-885

CAS: 1010100-07-8

CC-885 is a modulator of cereblon (CRBN). It has potent anti-tumour activity.

Formula: C₂₂H₂₁ClN₄O₄

Purity: 99.08% - 99.83%

Color and Shape: Solid

Molecular weight: 440.88

Ref: TM-T14893

N-(3-chloro-4-methylphenyl)-N'-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1-oxo-1H-isoindol-5-yl]methyl]-urea

CAS: 1010100-07-8

Formula: C₂₂H₂₁ClN₄O₄

Purity: 98%

Color and Shape: Solid

Molecular weight: 440.8795

Ref: IN-DA01EPNZ

CC-885

CAS: 1010100-07-8

CC-885

Purity: ≥98%

Molecular weight: 440.88g/mol

Ref: 54-BUP04187

CC-885

CAS: 1010100-07-8

Purity: 98%

Molecular weight: 440.125

Ref: 10-F549587

CC-885

CAS: 1010100-07-8

CC-885 is a pharmacologic agent that inhibits the ubiquitin ligases, which are enzymes that catalyze the transfer of ubiquitin to proteins. CC-885 has been shown to increase the levels of ubiquitinated proteins in cells and to inhibit their degradation by the proteasome. This drug has been shown to alter translation and cellular response pathways, leading to a clinical response in patients with chronic lymphocytic leukemia (CLL). It also acts as an immunomodulatory drug for lymphocytic leukemia, inhibiting transcriptional activation of NF-κB and NFAT in T cells. CC-885 is being developed for use as a cancer therapeutic agent. The mechanism of action is not fully understood, but it may be due to its ability to inhibit DNA replication or induce apoptosis.

Formula: C₂₂H₂₁ClN₄O₄

Purity: Min. 95%

Molecular weight: 440.88 g/mol

Ref: 3D-KQB10007